Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q1 2024 financial results and business update on May 13, 2024. Key highlights include $11.8 million in cash and cash equivalents, $170,000 in revenue (a 15% increase YoY), and ongoing cost reduction measures aiming for $10 million in annualized savings. The company is applying for $25 million in non-dilutive grants in the U.S. and $18 million in Europe. VolitionRx aims to achieve cash flow neutrality by 2025 through a mix of funding, revenue growth, and milestone payments. The company is focusing on commercializing its Nu.Q® NETs and Capture-PCR™ technologies, with new clinical data expected by the end of June 2024. A conference call to discuss these results is scheduled for May 14, 2024, at 8:30 a.m. U.S. Eastern Time.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled a conference call on May 14, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024 and provide a business update. The call will be hosted by key executives and will include details on important events and upcoming milestones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.